Skip to main content

Lord Global Comments on Recent review study at Cardiff University which demonstrated mouthwash (an Oral Sanitizer) may help prevent Covid-19 transmission

NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) — An article written in the July 18th, 2020 Knowridge Science Report said a recent review study at Cardiff University and elsewhere detailed that researchers found that certain mouthwashes used in the dental community may help destroy the lipid envelope of Coronaviruses. This would combat virus replication in the mouth and throat. The studies conclude that there is an urgent need to test the effectiveness of this approach in clinical studies. The article also highlighted that studies increasingly demonstrate the importance of the throat and salivary glands as sites of the virus replication and transmission in early COVID-19 disease. SAR-COV-2 is an enveloped virus characterized by an outer lipid membrane derived from the host cell from which it buds. The virus is highly sensitive to agents that disrupt lipid bio-membranes.
Joseph Frontiere, CEO of Lord Global Inc. (OTC:LRDG)  and 27Health Inc., said, “We are excited to find studies demonstrating the need for a mouthwash, which is an Oral Sanitizer, that can disrupt the virus’s lipid membrane. Our product’s (an oral sanitizer powered by our patent pending ingredient combinations) mechanism of action does exactly that. In addition, it contains other products which are virucidal as well as immune boosting. All of our ingredients are used currently and our product will carry an FDA OTC moniker. We believe this product will be the first Oral Sanitizer on the market. We are launching the product in August 2020. While the key ingredients have had numerous studies showing its virucidal properties, including on other coronavirus family members, we are presently testing it on the pandemic virus itself. 27Health Inc. acquired the marketing rights to the product family from CoviGuard Inc. the product’s inventor. We will launch an oral spray as well as two sizes of the mouthwash in addition to a nasal spray. We already sense a growing demand for the product family. Studies such as the ones in the Knowridge article demonstrate our instincts were correct. We believe this will be our signature product.”The article was found here
https://www.newsbreak.com/news/1602623832976/mouthwash-may-help-prevent-covid-19-transmission-this-study-shows?s=oldSite&ss=a4
About Lord Global CorporationLord Global Corporation intends to focus on the business development of its 27health Inc. subsidiary. 27Health Inc. is dedicated to financing and marketing innovative, healthcare related products that are and will benefit from the permanent changes caused by the COVID-19 pandemic. It is our feeling that this crisis has accelerated the market share of direct to consumer healthcare products and services. Prior to the crisis, the direct to consumer cloud based market was among the fastest growing, subsequent to this crisis, we believe that 10 years worth of market share has been condensed into several months. Hence, we have signed collaboration and distribution agreements with several companies. We believe that focusing on independent contractors and GIG-economy workers for all these products and services will help us in cross-selling each of these products and services to the same database. The Independent contractor and GIG-economy worker has been and is the fastest growing component of the U.S. labor supply and is estimated to be at least 60 million people. The pandemic is teaching individuals forced to work from their home to become adept at telecommuting. We believe coming out of this crisis, a large number of these individuals will prefer to work from their phones and computers and from any location as opposed to a fixed office. This will hyper-accelerate the already significant growth of this component of the U.S. labor supply. We believe that marketing health related products and services to this market will make us one of the fastest growing healthcare marketing companies.Safe Harbor StatementThis press release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. For example, statements about future revenues and the Company’s ability to fund its operations and contractual obligations are forward looking and subject to risks. Several important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, the inability to raise capital to support the Company through its growth stage, the Company’s inability to generate projected sales and trade relations between the United States. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.27Health, Inc. PR Contact Information
Sean Carter
info@27health.net

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.